AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OPTHEA LTD

0.600

+0.000

Apr 11 16:12 AEDT delayed 15 min

Volume:- -

Turnover:- -

Market Cap:738.77M

PE:-1.43

High:0.600

Open:0.600

Low:0.600

Close:0.600

1D

5D

D

W

M

Q

Y

1m

5m

10m

15m

30m

1h

2h

More

1D

5D

D

W

M

Q

Y

1m

5m

10m

15m

30m

1h

2h

Loading ...

Overview Company News Filings

Opthea Requests Trading Halt

MT Newswires Live

BRIEF-Opthea Seeks Trading Halt

Opthea Ltd - Seeks Trading Halt Pending Announcement on Top Line Results of Its Phase 3 Coast Clinical Trial

THOMSON REUTERS

Exploring Three High Growth Tech Stocks In Australia

Simply Wall St.

Opthea First Half 2025 Earnings: US$0.11 loss per share (vs US$0.17 loss in 1H 2024)

Simply Wall St.

Opthea Says Trial Data for Eye Disease Drug Candidate Published in Peer-Reviewed Journal

MT Newswires Live

Press Release: Opthea Reports Half Year Results and Business Updates

Opthea Posts Narrower Fiscal H1 Loss, Lower Revenue

MT Newswires Live

BRIEF-Opthea Says HY Loss From Ordinary Activities Before Tax Increased To $137.9 Million

Corrected-Opthea Ltd - Hy Loss From Ordinary Activities Before Tax Increased 29% to $137.9 Mln (Corrects Currency to $ From a$)

THOMSON REUTERS

Opthea Completes Drug Product PPQ Campaign

Opthea Demonstrates Production of Multiple Batches of Age-Related Macular Degeneration Drug Candidate, Shares Fall 5%

MT Newswires Live

Wilsons Upgrades Opthea to Market-Weight from Underweight; Price Target is AU$1

MT Newswires Live

Opthea Ltd -Confirms Topline Results for Coast Anticipated in Early 2Q Cy25

THOMSON REUTERS

ASX Midday Sector Update: Healthcare Sector Rises, Energy Stocks Plunge

MT Newswires Live

Opthea Completes Final Patient Visit in Phase Three Trial of Eye Disease Combination Therapy Candidate

MT Newswires Live

Is Opthea Limited (OPT) the Best Long Term ASX Stock to Buy Now?

Experts reveal 4 ASX small-cap shares to buy now

High Growth Tech Stocks To Explore In February 2025

Simply Wall St.

Opthea Wet AMD Data Featured at Macula Society Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OPT.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OPT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPT.AU\",,,,,undefined,":{"symbol":"OPT.AU","market":"AU","secType":"STK","nameCN":"OPTHEA LTD","latestPrice":0.6,"timestamp":1744351920000,"preClose":0.6,"halted":0,"volume":0,"delay":0,"nameEN":"OPTHEA LTD","floatShares":786007538,"shares":1231287336,"eps":-0.4186841686555291,"marketStatus":"Market Closed","change":0,"latestTime":"04-11 16:12:00 AEST","open":0.6,"high":0.6,"low":0.6,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.4186841686555291,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1744588800000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.6,"openAndCloseTimeList":[[1744329600000,1744351200000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPT.AU\",,,,,undefined,":{"symbol":"OPT.AU","floatShares":786007538,"roa":"-73.34%","roe":"-3383.08%","lyrEps":-0.54908,"shares":1231287336,"dividePrice":0,"high":0.6,"amplitude":0,"preClose":0.6,"low":0.6,"week52Low":0.335,"pbRate":"-2.75","psRate":"2223.12","week52High":1.165,"institutionHeld":0,"latestPrice":0.6,"eps":-0.4186841686555291,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.4186841686555291,"open":0.6,"prevYearClose":0.81,"prevWeekClose":0.6,"prevMonthClose":0.6,"prevQuarterClose":0.6,"fiveDayClose":0.6,"twentyDayClose":0.6,"sixtyDayClose":0.775},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OPT.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2520629580","title":"Opthea Requests Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2520629580","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520629580?lang=en_us&edition=fundamental","pubTime":"2025-03-17 07:45","pubTimestamp":1742168746,"startTime":"0","endTime":"0","summary":"Opthea  requested that its securities be placed in trading halt until an announcement related to results of its Phase 3 Combination OPT-302 with Aflibercept Study  clinical trial is made, according to a Monday filing with the Australian bourse.The trading halt will remain in place until the start of trading on March 19 or when the company makes the announcement about the COAST results, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","OPT","BK4139","OPT.AU"],"gpt_icon":0},{"id":"2520581786","title":"BRIEF-Opthea Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2520581786","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520581786?lang=en_us&edition=fundamental","pubTime":"2025-03-17 05:57","pubTimestamp":1742162230,"startTime":"0","endTime":"0","summary":"BRIEF-Opthea Seeks Trading HaltMarch 17 (Reuters) - Opthea Ltd OPT.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON TOP LINE RESULTS OF ITS PHASE 3 COAST CLINICAL TRIALFurther company coverage: OPT.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250316:nFWN3PY00H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPT.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2520558193","title":"Opthea Ltd - Seeks Trading Halt Pending Announcement on Top Line Results of Its Phase 3 Coast Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2520558193","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520558193?lang=en_us&edition=fundamental","pubTime":"2025-03-17 05:41","pubTimestamp":1742161316,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250316:nFWN3PY00H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OPT.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2518779823","title":"Exploring Three High Growth Tech Stocks In Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2518779823","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518779823?lang=en_us&edition=fundamental","pubTime":"2025-03-12 03:05","pubTimestamp":1741719951,"startTime":"0","endTime":"0","summary":"In the current Australian market landscape, the ASX200 has recently experienced a downturn, closing down 0.9% at 7,890 points with IT being the worst-performing sector. Despite this challenging environment, identifying high-growth tech stocks requires careful consideration of their innovation potential and resilience in navigating volatile conditions.Click here to see the full list of 52 stocks from our ASX High Growth Tech and AI Stocks screener.Operations: The company generates revenue primarily from the provision of backup services, amounting to A$41.17 million.Click here to discover the nuances of Dropsuite with our detailed analytical health report.Overview: Nuix Limited offers investigative analytics and intelligence software solutions across various regions including the Asia Pacific, the Americas, Europe, the Middle East, and Africa with a market cap of approximately A$1.13 billion.Operations: Nuix generates revenue primarily from its Software & Programming segment, which accou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-three-high-growth-tech-190551662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","DSE.AU","OPT","NXL.AU","OPT.AU"],"gpt_icon":0},{"id":"2517929091","title":"Opthea First Half 2025 Earnings: US$0.11 loss per share (vs US$0.17 loss in 1H 2024)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517929091","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517929091?lang=en_us&edition=fundamental","pubTime":"2025-03-06 04:38","pubTimestamp":1741207106,"startTime":"0","endTime":"0","summary":"ASX:OPT Earnings and Revenue History March 5th 2025. All figures shown in the chart above are for the trailing 12 month  period. Looking ahead, revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Biotechs industry in Australia.The company's shares are down 18% from a week ago.You still need to take note of risks, for example - Opthea has   4 warning signs   we think you should be aware of.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opthea-first-half-2025-earnings-203826235.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OPT","OPT.AU"],"gpt_icon":1},{"id":"2516364524","title":"Opthea Says Trial Data for Eye Disease Drug Candidate Published in Peer-Reviewed Journal","url":"https://stock-news.laohu8.com/highlight/detail?id=2516364524","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516364524?lang=en_us&edition=fundamental","pubTime":"2025-03-03 09:43","pubTimestamp":1740966234,"startTime":"0","endTime":"0","summary":"Opthea  announced the publication of data from a phase 2b trial of its sozinibercept drug candidate for wet age-related macular degeneration in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina, according to a Monday Australian bourse filing.The paper reports pre-specified and post-hoc analyses of angiographic predictors of response to sozinibercept combination therapy with ranibizumab in treatment-nave patients.The randomized, controlled trial saw sozinibercept combination therapy leading to superior visual gains compared to therapy with only ranibizumab at 24 weeks.Analysis of the data showed that in patients with occult and minimally classic lesions, representing 73% of the Phase 2b total patient population, sozinibercept combination therapy demonstrated a \"statistically significant\" gain in best corrected visual acuity compared to ranibizumab alone.Opthea's shares rose almost 3% in recent trading on Monday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","OPT.AU","OPT","BK7508"],"gpt_icon":0},{"id":"2514585323","title":"Press Release: Opthea Reports Half Year Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2514585323","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514585323?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:00","pubTimestamp":1740744000,"startTime":"0","endTime":"0","summary":"Cash and cash equivalents of $131.9M as of December 31, 2024. Cash runway extends through anticipated topline data readouts of COAST  and ShORe . \"Opthea is making significant progress on its mission to deliver superior vision to patients with wet AMD enabling them to live fuller and healthier lives,\" said Frederic Guerard, PharmD, Chief Executive Officer of Opthea. \"Sozinibercept has the potential to be the first product in nearly 20 years to demonstrate superior visual outcomes in combination with standard of care therapy, and we look forward to the anticipated topline data readouts of our two Phase 3 clinical trials in early Q2 and mid-calendar year 2025.\". Tom Reilly, Chief Financial Officer of Opthea, added: \"Looking ahead, we expect our cash and cash equivalents to fund the Company through the anticipated topline data readouts of the Phase 3 COAST and ShORe trials. In addition, we continue to progress our manufacturing  activities as we prepare our Biologics License Application  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823421333.USD","IE00BMPRXN33.USD","BK4141","IE00BKVL7J92.USD","LU0823421416.USD","LU1852331112.SGD","GFS","LU2360106780.USD","LU1316542783.SGD","OPT.AU","LU1303367103.USD","LU1951198990.SGD","LU0149725797.USD","BK4139","LU2250418816.HKD","BK4006","IE00B5949003.HKD","IE0009356076.USD","IE00BHPRN162.USD","LU2458330169.SGD","LU0127658192.USD","LU1880398471.USD","OPT","BK4543","LU0056508442.USD","BK4585","BK7508","BK7067","LU0642271901.SGD","BK4575","LU0390134368.USD","LU0971096721.USD","BK4532","IE00BMPRXR70.SGD","LU2098885051.SGD","LU1803068979.SGD","LU1951200564.SGD","LU0719512351.SGD","BK4573","BK4566","LU0170899867.USD","LU0979878070.USD","LU0823434583.USD","BK4529","CMC","LU1989764664.SGD","LU0889565833.HKD","LU1923623000.USD","LU2458330243.SGD"],"gpt_icon":1},{"id":"2514357685","title":"Opthea Posts Narrower Fiscal H1 Loss, Lower Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2514357685","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514357685?lang=en_us&edition=fundamental","pubTime":"2025-02-28 08:02","pubTimestamp":1740700931,"startTime":"0","endTime":"0","summary":"Opthea  reported Friday that its loss per diluted share in the fiscal first half narrowed to $0.108 from $0.172 a year earlier.Analysts polled by Visible Alpha were expecting a loss of $0.14 per diluted share.Total revenue for the six months ended Dec. 31, 2024, was $149,000, down from $202,000 in the same period a year earlier. Analysts surveyed by Visible Alpha expected $100,000.Company shares were down 2% in recent Friday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPT","OPT.AU"],"gpt_icon":0},{"id":"2514333353","title":"BRIEF-Opthea Says HY Loss From Ordinary Activities Before Tax Increased To $137.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514333353","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514333353?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:24","pubTimestamp":1740691497,"startTime":"0","endTime":"0","summary":"BRIEF-Opthea Says HY Loss From Ordinary Activities Before Tax Increased To $137.9 MillionFeb 28  - Opthea Ltd OPT.AX:HY LOSS FROM ORDINARY ACTIVITIES BEFORE TAX INCREASED 29% TO $137.9 MILLION HY REVENUES FROM ORDINARY ACTIVITIES $24,000Further company coverage: OPT.AX  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL5N3PI378:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","OPT.AU"],"gpt_icon":0},{"id":"2514584013","title":"Corrected-Opthea Ltd - Hy Loss From Ordinary Activities Before Tax Increased 29% to $137.9 Mln (Corrects Currency to $ From a$)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514584013","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514584013?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:24","pubTimestamp":1740691496,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL5N3PI378:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OPT.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2514083913","title":"Opthea Completes Drug Product PPQ Campaign","url":"https://stock-news.laohu8.com/highlight/detail?id=2514083913","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514083913?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:00","pubTimestamp":1740571200,"startTime":"0","endTime":"0","summary":"Three consecutive commercial-scale drug product batches successfully produced. Supports potential sozinibercept BLA filing in 1H CY2026. The PPQ campaign consisted of the successful production of three consecutive commercial-scale drug product batches required to further validate Opthea’s manufacturing process in preparation for a potential biologics license application  filing and commercialization of sozinibercept in wet AMD. The batches have been produced subsequent to the successful completion of the drug substance PPQ campaign announced in September 2024.There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opthea-completes-drug-product-ppq-120000914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0004445239.USD","LU0719512351.SGD","LU0823434740.USD","LU2264538146.SGD","LU1242518857.USD","LU1064131342.USD","LU1242518931.SGD","LU1923623000.USD","LU0642271901.SGD","BK4605","LU0823421416.USD","LU1951200564.SGD","BK4139","LU1852331112.SGD","LU0109392836.USD","BK4512","BK4534","LU1880398554.USD","LU0889565833.HKD","BK4554","LU1951198990.SGD","IE00BMPRXN33.USD","IE00B5949003.HKD","LU1316542783.SGD","LU2458330169.SGD","LU0082616367.USD","BK4543","LU1303367103.USD","LU0127658192.USD","GFS","OPT","BK4141","LU2250418816.HKD","LU0823421333.USD","BK4566","BK4588","BK4585","LU0390134368.USD","LU0979878070.USD","LU2360106780.USD","BK4575","LU0823434583.USD","LU1988902786.USD","OPT.AU","LU2098885051.SGD","LU2054465674.USD","LU1803068979.SGD","LU0056508442.USD","LU0081259029.USD","BK4573"],"gpt_icon":1},{"id":"2514802754","title":"Opthea Demonstrates Production of Multiple Batches of Age-Related Macular Degeneration Drug Candidate, Shares Fall 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514802754","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514802754?lang=en_us&edition=fundamental","pubTime":"2025-02-26 09:47","pubTimestamp":1740534463,"startTime":"0","endTime":"0","summary":"Opthea  completed its drug product process performance qualification campaign for its sozinibercept drug candidate to treat wet age-related macular degeneration, demonstrating its ability to consistently manufacture the candidate at a commercial scale, according to a Wednesday Australian bourse filing.The campaign consisted of the production of three consecutive commercial-scale drug product batches.This was required to further validate its manufacturing process in preparation for a potential biologics license application filing, as well as the commercialization of sozinibercept, in the first half of 2026.The firm's shares fell 5% in early trading on Wednesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPT.AU","OPT","BK4139","BK7508","BK7067"],"gpt_icon":0},{"id":"2512415180","title":"Wilsons Upgrades Opthea to Market-Weight from Underweight; Price Target is AU$1","url":"https://stock-news.laohu8.com/highlight/detail?id=2512415180","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512415180?lang=en_us&edition=fundamental","pubTime":"2025-02-20 16:48","pubTimestamp":1740041303,"startTime":"0","endTime":"0","summary":"Opthea (ASX:OPT) has an average rating of outperform and price targets ranging from AU$0.28 to AU$2.71, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and economic r","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPT","OPT.AU"],"gpt_icon":0},{"id":"2512587011","title":"Opthea Ltd -Confirms Topline Results for Coast Anticipated in Early 2Q Cy25","url":"https://stock-news.laohu8.com/highlight/detail?id=2512587011","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512587011?lang=en_us&edition=fundamental","pubTime":"2025-02-18 19:07","pubTimestamp":1739876878,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250218:nFWN3P80ZO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","OPT.AU","BK7067"],"gpt_icon":0},{"id":"2512972901","title":"ASX Midday Sector Update: Healthcare Sector Rises, Energy Stocks Plunge","url":"https://stock-news.laohu8.com/highlight/detail?id=2512972901","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512972901?lang=en_us&edition=fundamental","pubTime":"2025-02-18 10:45","pubTimestamp":1739846741,"startTime":"0","endTime":"0","summary":"Healthcare stocks advanced 0.3% at midday Tuesday. The Reserve Bank of Australia is expected to announce the anticipated interest rate decision later on the same day.Opthea  completed the final week-52 patient visit in Coast, the first of two phase three trials evaluating a combination therapy candidate for wet age-related macular degeneration, an eye disease that can blur vision.On the other hand, energy stocks were down 1.7%. Woodside Energy Group  extended losses from the Monday trading session, after it implied its final dividend could fall below expectations by as much as 20%.Woodside held talks with several potential buyers of stakes in its Louisiana liquefied natural gas plant, including Tokyo Gas, Japan's JERA, and MidOcean Energy, Reuters reported citing multiple sources.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPT.AU","BK7142","BK7067","BK7508","BK4137","WDS.AU","HCSG"],"gpt_icon":1},{"id":"2512038379","title":"Opthea Completes Final Patient Visit in Phase Three Trial of Eye Disease Combination Therapy Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2512038379","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512038379?lang=en_us&edition=fundamental","pubTime":"2025-02-18 09:17","pubTimestamp":1739841467,"startTime":"0","endTime":"0","summary":"Opthea  completed the final week-52 patient visit in Coast, the first of two phase three trials evaluating a combination therapy candidate for wet age-related macular degeneration, an eye disease that can blur vision, according to a Tuesday Australian bourse filing.The trial is investigating the superiority and safety of its drug candidate, sozinibercept, in combination with aflibercept, compared with the standard of care alone.The company is also conducting a concurrent phase three trial assessing the combination of sozinibercept with ranibizumab.Beyond week 52, patients will continue to be treated for an additional year to evaluate extended safety and tolerability up to a two-year period, the filing said.Top-line results from the Coast trial are anticipated in the second quarter.The company's shares were up almost 1% in recent Tuesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","OPT","OPT.AU"],"gpt_icon":0},{"id":"2510358337","title":"Is Opthea Limited (OPT) the Best Long Term ASX Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2510358337","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510358337?lang=en_us&edition=fundamental","pubTime":"2025-02-12 01:01","pubTimestamp":1739293307,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Long Term ASX Stocks to Buy Now.In this article, we are going to take a look at where Opthea Limited  stands against the other long term ASX stocks.Vanguard believes that Australia's economy remains well-placed to recover gradually in 2025 after the broader economy witnessed its slowest growth in 32 years in 2024 amid sticky inflation and higher interest rates. The investment firm expects modest improvement in economic momentum, courtesy of higher real household incomes as inflation subsides. Furthermore, a rebounding housing market and expectations of rate cuts might also provide some support.Key Indicators Likely to Shape Australia's Economy in 2025. The Reserve Bank of Australia  kept the policy rate target unchanged at 4.35% on December 10. However, the bank noted that it continues to see signs of inflation moving sustainably towards the target. That being said, Vanguard expects that RBA will remain patient and that a tight labor market is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opthea-limited-opt-best-long-170147873.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["QLD","PSQ","BK7508","LU2098885051.SGD","TQQQ","XAO.AU","OPT","LU1815336091.USD","XKO.AU","MNQmain","BK4137","USJW.SI","QID","SQQQ","CKDXF","BK7067","BK4139","NQmain","TSYW.SI","LU0757428866.USD","OPT.AU","USAW.SI","XJO.AU",".IXIC","NVIW.SI","RBA","LU1303367103.USD"],"gpt_icon":1},{"id":"2510480131","title":"Experts reveal 4 ASX small-cap shares to buy now","url":"https://stock-news.laohu8.com/highlight/detail?id=2510480131","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510480131?lang=en_us&edition=fundamental","pubTime":"2025-02-11 09:05","pubTimestamp":1739235950,"startTime":"0","endTime":"0","summary":"Nuix Ltd  The Nuix share price is $4.74, down 0.63%. Moelis Australia has a buy rating on this ASX small-cap tech share with a price target of $6.09. Moelis responded to Nuix's 1H FY25 update, which stated it was expecting 8% to 9% growth in Annualised Contract Value  compared to the previ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/11/experts-reveal-4-asx-small-cap-shares-to-buy-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["ACV","OPT.AU","BK7508","BMN.AU","OPT","XJO.AU","BK7067","BK4139","NXL.AU","BK7016","BK7083","PYC.AU"],"gpt_icon":0},{"id":"2510283844","title":"High Growth Tech Stocks To Explore In February 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2510283844","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510283844?lang=en_us&edition=fundamental","pubTime":"2025-02-10 12:02","pubTimestamp":1739160134,"startTime":"0","endTime":"0","summary":"The Australian market has recently experienced a downturn, with the ASX200 down 0.36% amid negative reactions to impending U.S. tariffs on Australian aluminium and steel, while IT and Technology sectors have notably declined by 1.2%. In this challenging environment, identifying high growth tech stocks involves looking for companies that demonstrate resilience and adaptability in the face of economic pressures and sector-specific challenges.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-dse/dropsuite-shares/news/high-growth-tech-stocks-to-explore-in-february-2025-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["OPT.AU","BK7016","DSE","BK7508","XAO.AU","DSE.AU","OPT","XKO.AU","BK4139","XJO.AU","BK7067","NXL.AU"],"gpt_icon":0},{"id":"2509222428","title":"Opthea Wet AMD Data Featured at Macula Society Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2509222428","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509222428?lang=en_us&edition=fundamental","pubTime":"2025-02-06 20:00","pubTimestamp":1738843200,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, and PRINCETON, N.J., Feb. 06, 2025  -- Opthea Limited , a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration , today announced that sozinibercept will be highlighted during an oral presentation at the Macula Society 48th Annual Meeting being held February 12-15, 2025 in Charlotte Harbor, Florida. The Macula Society is a forum for new research in retinal vascular and macular diseases.David S. Boyer, MD will present data from the sozinibercept Phase 2b wet AMD trial demonstrating that superior vision and anatomic outcomes were observed with sozinibercept 2 mg combination therapy, compared with standard-of-care ranibizumab alone, with baseline angiographic lesion characteristics predictive of response.Opthea’s lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C/D ‘trap’ inhibitor being evaluated in combinatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opthea-wet-amd-data-featured-120000850.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4141","LU2458330169.SGD","LU2250418816.HKD","LU0390134368.USD","BK4532","LU0979878070.USD","LU0127658192.USD","LU0889565833.HKD","LU1880398471.USD","LU2054465674.USD","LU0642271901.SGD","LU1880398554.USD","LU2264538146.SGD","LU2360106780.USD","BK4512","BK4575","LU0081259029.USD","AMD","LU0082616367.USD","LU0719512351.SGD","LU0109392836.USD","LU1989764664.SGD","LU1316542783.SGD","BK4554","IE00BMPRXR70.SGD","LU0823421416.USD","GFS","LU1951200564.SGD","LU2458330243.SGD","IE0009356076.USD","IE00B5949003.HKD","BK4573","LU0056508442.USD","LU1852331112.SGD","BK4529","BK4588","LU1803068979.SGD","BK4566","LU1923623000.USD","BK4534","LU1242518931.SGD","OPT.AU","LU0823434583.USD","BK4139","OPT","LU1303367103.USD","BK4585","LU1064131342.USD","LU0823421333.USD","BK4543","LU1988902786.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":77,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OPT.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OPT.AU\",market:\"AU\",,,undefined,":[]}}

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."

Consult now
Download APP
Scan QR code to download the app.